ライフサイエンスコーパス: drug discovery

1 ich has led to renewed efforts in antibiotic drug discovery.

2 biological molecule visualization and modern drug discovery.

3 t could be highly impactful for neuroscience drug discovery.

4 o target this family of proteins for further drug discovery.

5 hat PKD may represent a target for antiviral drug discovery.

6 r diseases making them promising targets for drug discovery.

7 these organisms and provide new targets for drug discovery.

8 hallmarks that represent common targets for drug discovery.

9 omponent in minimizing off-target effects in drug discovery.

10 ology, and also represent a new platform for drug discovery.

11 t for the usefulness of GWAS data in guiding drug discovery.

12 o elucidate disease pathology and facilitate drug discovery.

13 nes which are attractive building blocks for drug discovery.

14 elds, such as proteomics, interactomics, and drug discovery.

15 ore they represent viable targets for cancer drug discovery.

16 a, and in silico prediction tools for modern drug discovery.

17 uM, i.e., conditions typically accessible in drug discovery.

18 tary tools for hit and lead optimizations in drug discovery.

19 tively is of great importance, especially in drug discovery.

20 parasite is poorly understood which hinders drug discovery.

21 ks of high value for medicinal chemistry and drug discovery.

22 f paramount importance in the early stage of drug discovery.

23 owerful tool for compound selection in early drug discovery.

24 portunity to reduce the attrition problem in drug discovery.

25 ulators bind and provides a path forward for drug discovery.

26 ew avenues for early disease diagnostics and drug discovery.

27 ad identification and optimization for early drug discovery.

28 lpyridines, an attractive substance class in drug discovery.

29 receptor antagonists in the early phases of drug discovery.

30 ncer research, stem-cell differentiation and drug discovery.

31 et class activities commonly investigated in drug discovery.

32 and innovative H2S donors for cardiovascular drug discovery.

33 e immediate consequences for structure-based drug discovery.

34 f cheminformatics-based, complement-directed drug discovery.

35 e development of cell-based assays for NMDAR drug discovery.

36 rovides the possibility of novel targets for drug discovery.

37 omising natural product derived scaffold for drug discovery.

38 t of high-throughput screening platforms for drug discovery.

39 rases are proving to be fruitful targets for drug discovery.

40 -1beta interaction is a potential target for drug discovery.

41 eractions, would open vast opportunities for drug discovery.

42 functionalization in late-stage heterocycle drug discovery.

43 ing their further exploration for anticancer drug discovery.

44 Here we review the current status of ZIKV drug discovery.

45 enome to be exploited for basic research and drug discovery.

46 sease-relevant phenotypes in order to enable drug discovery.

47 the potential of lysine targeting for future drug discovery.

48 s permeability to BBB is prerequisite in CNS drug discovery.

49 or applications in glycobiology research and drug discovery.

50 o see widespread applications in early-stage drug discovery.

51 P1/15LO complexes represent a new target for drug discovery.

52 lementation of these models, particularly in drug discovery.

53 to release H2S represents a timely issue for drug discovery.

54 developmental biology, forward-genetics, and drug discovery.

55 that improve the efficacy and efficiency of drug discovery.

56 rature-based database focused on preclinical drug discovery.

57 enewed interest as an efficient strategy for drug discovery.

58 e a broad utility in medicinal chemistry and drug discovery.

59 bstantially higher dynamic window for aiding drug discovery.

60 s key to direct lead optimization efforts in drug discovery.

61 tive cellular model for toxin evaluation and drug discovery.

62 re prospects of the dimerization concept for drug discovery.

63 screening is one of the major approaches in drug discovery.

64 ng of the aggregation process as well as for drug discovery.

65 esents an attractive target for tuberculosis drug discovery.

66 blocks and fragments with potential value in drug discovery.

67 Nature offers an abundance of compounds for drug discovery.

68 ted EGFR can help identify novel targets for drug discovery.

69 are promising sources of small molecules for drug discovery.

70 biological reagents for target validation in drug discovery.

71 rexpressed, making it a potential target for drug discovery.

72 ecoming an increasingly popular strategy for drug discovery.

73 cessory proteins provide a new dimension for drug discovery.

74 posure is a major cause of high attrition in drug discovery.

75 identification of new potential targets for drug discovery.

76 guidelines for exploiting water molecules in drug discovery.

77 potential promising leads for antiplasmodial drug discovery.

78 omise as a biomarker for diagnosis and novel drug discovery.

79 ectroscopy has become an established tool in drug discovery.

80 osis metabolic processes and new targets for drug discovery.

81 cle and are validated targets for anticancer drug discovery.

82 egenerative therapies, disease modeling, and drug discovery.

83 g new hA3R antagonists in the early phase of drug discovery.

84 stem for accelerated mechanistic studies and drug discovery.

85 prepared to venture into new territories of drug discovery.

86 provide new opportunities for biomarker and drug discoveries.

87 iting applications in precision medicine and drug discovery and aid in the development of increased a

88 en widely recognized as potential targets in drug discovery and aptamer selection.

89 tform will have a variety of applications in drug discovery and cellular biology by facilitating the

90 an important information resource supporting drug discovery and chemical biology research.

91 Fragment-based drug discovery and continuous improvement of existing pr

92 limited by difficulties with small molecule drug discovery and development and an under appreciation

93 in the functionality evaluation not only in drug discovery and development but also in quality contr

94 These studies are expected to facilitate drug discovery and development efforts toward new antiba

95 Herein, we summarize the advances in drug discovery and development of BRD4 inhibitors by foc

96 form toxicology risk assessment, and improve drug discovery and development.

97 e imaging of clinical tissue samples, and in drug discovery and development.

98 Globalization has driven new paradigms for drug discovery and development.

99 oad application across biochemical study and drug discovery and development.

100 tware, this method can be very beneficial in drug discovery and development.

101 used, which should be of broad relevance to drug discovery and disease treatment.

102 omotion of translational research, including drug discovery and drug target identification.

103 s a translational end point in pro-cognitive drug discovery and early-phase clinical trials.

104 ut model with translational implications for drug discovery and genetic modifiers of chemotherapy-ind

105 Ligand-binding assays are the linchpin of drug discovery and medicinal chemistry.

106 e in virus lifecycles and in applications to drug discovery and nanomaterial development.

107 yields access to patient-specific cells for drug discovery and personalized medicine.

108 Cs can be used for studying cardiac biology, drug discovery and regenerative medicine.

109 ological data provides new opportunities for drug discovery and repositioning.

110 rug design is an integral part of modern day drug discovery and requires detailed structural characte

111 nd unintended drug actions and to facilitate drug discovery and screening.

112 Driven by the ever-increasing pace of drug discovery and the need to push the boundaries of un

113 loops and has great potential to be used in drug discovery and toxicology studies.

114 interaction is important for structure-based drug discovery and understanding protein structure-funct

115 More representative models are required for drug discovery and validation.

116 n effective and robust tool for MCU-specific drug discovery and, more generally, for the identificati

117 s on transplantation, regenerative medicine, drug discovery, and a variety of rapidly advancing areas

118 istry, molecular sensors, materials science, drug discovery, and catalysis.

119 e of hiPSCs to study disease mechanisms, for drug discovery, and eventually for cell replacement ther

120 technology has been extensively employed in drug discovery, and it has already led to the discovery

121 f the ProTide technology, its application in drug discovery, and its role in the improvement of drug

122 ical tools, highlighting potential areas for drug discovery, and mechanisms of approved drugs.

123 nt for investigations of disease mechanisms, drug discovery, and signaling-network studies.

124 e as a promising candidate for anti-diabetic drug discovery; and b) provide a rational basis for the

125 In a drug discovery application on HSP90, we show the method

126 ation in human traits, as well as supporting drug discovery applications.

127 ar progenitors for regenerative medicine and drug discovery applications.

128 is study, we have employed a cheminformatics drug discovery approach based on the extensive structura

129 Quantitative Systems Pharmacology (QSP) is a drug discovery approach that integrates computational an

130 s drug repurposing is becoming an attractive drug discovery approach, recent repurposing studies of c

131 proof-of-concept, validating the biology and drug discovery approach.

132 We used structure-based drug discovery approaches to develop potent, selective,

133 ce is therefore important not only to devise drug discovery approaches, but also to gain knowledge on

134 The majority of breast cancer models for drug discovery are based on orthotopic or subcutaneous t

135 broad applications in organic synthesis and drug discovery are demonstrated in the synthesis of nove

136 We note a watershed in osteoporosis drug discovery around the year 2000, when the approach t

137 hibitors have gained widespread attention in drug discovery as a validated method to circumvent acqui

138 thesis of medicinally relevant compounds for drug discovery, as well as the degradation of biological

139 ss rates and reducing risk in small molecule drug discovery, as, based on our previous analysis, appr

140 pyrrolopyrimidine AEE788 (a hit for anti-HAT drug discovery) associates with three trypanosome protei

141 oactivity, they have largely been ignored in drug discovery because of their presumed indiscriminate

142 ens and are promising targets for antifungal drug discovery because their domain compositions and bio

143 Although fragment-based drug discovery benefits immensely from access to atomic-

144 To facilitate network-based approaches to drug discovery, BioGRID now incorporates 27 501 chemical

145 e analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles

146 portunities in screening and structure-aided drug discovery, but could also be exploited as therapeut

147 e expected to significantly accelerate Hsp70 drug discovery by providing XIAP as a pharmacodynamic bi

148 A fragment-based drug discovery campaign against human caspase-7 resulted

149 The hit validation stage of a fragment-based drug discovery campaign involves probing the SAR around

150 However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) ch

151 This method has become a central facet of drug discovery campaigns in the pharmaceutical industry

152 We consider what ophthalmic drug discovery can learn from the sector in general and

153 mation of new relationships between academic drug discovery centers and commercial partners, which ca

154 provides examples of how it may be used in a drug discovery context.

155 to develop efficient methods for early-stage drug discovery, continuous manufacturing of drug deliver

156 Using computer-aided drug discovery coupled with in vitro kinase assays, we i

157 derstanding the thermodynamics specific to a drug discovery/design study is well known.

158 and bottom-up tissue engineering, as well as drug discovery, developmental biology, neuroscience, and

159 inoma may be a valuable approach to diabetes drug discovery.Diabetes results in part from a deficienc

160 is burdened by many uncertainties that make drug discovery difficult.

161 to iCPCs provides a scalable cell source for drug discovery, disease modeling, and cardiac regenerati

162 ortant to a broad range of fields, including drug discovery, ecology, biosynthesis, and chemical biol

163 Drug discovery efforts against the pathogen Mycobacteriu

164 n a variety of human cancers have stimulated drug discovery efforts aimed at restoring PP2A function

165 These data and samples have promoted drug discovery efforts and research into genomics and qu

166 The drug discovery efforts and strategies that resulted in t

167 oupled receptors (GPCRs) pose challenges for drug discovery efforts because of the high degree of str

168 Thus, drug discovery efforts have focused on the restoration o

169 Recent drug discovery efforts have focused primarily on alloste

170 ase binding affinity with relevance to other drug discovery efforts in targeted protein degradation.

171 we present a strategic framework for future drug discovery efforts in this pathway beyond the target

172 de topical coverage of target validation and drug discovery efforts made in targeting these oncogenic

173 nsight into the RGS family members for which drug discovery efforts may be most likely to succeed.

174 d future pathway research may help focus new drug discovery efforts on key novel targets and mechanis

175 Approaches range from drug discovery efforts to big-data methods and direct-to

176 modality-specific manner and help to direct drug discovery efforts towards novel visceral analgesics

177 resolution insight is beginning to transform drug discovery efforts, and there are a number of GPCR d

178 t validation is essential for the success of drug discovery efforts.

179 which will be required to guide future MELK drug discovery efforts.

180 sion, which can aid in future antidepressant drug discovery efforts.

181 enzymes, and provides a new path forward for drug discovery efforts.

182 protein crystallography in structure-guided drug discovery emerged as enzyme structures allowed the

183 studies, and will undoubtedly assist future drug discovery endeavors.

184 ons, including clinical biomarker discovery, drug discovery, environmental chemistry, and metabolomic

185 A fragment-based drug discovery (FBDD) approach was utilized to identify

186 The popularity of fragment-based drug discovery (FBDD) is demonstrated by the number of r

187 Fragment-based drug discovery (FBDD) is now well-established as a techn

188 By utilization of fragment-based drug discovery (FBDD), a new class of inhibitors for NDM

189 ould greatly aid in iterative fragment-based drug discovery (FBDD).

190 tly by the FDA and major stakeholders in the Drug Discovery field for the validation of the Comprehen

191 Whereas the drug discovery field has largely been driven by target-b

192 be of value to both the chemical biology and drug discovery fields.

193 ypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to

194 s, which can be used in disease modeling and drug discovery for colorectal disease.

195 Despite these remarkable advances in drug discovery for FD, we lacked a phenotypic mouse mode

196 rce the value of computational approaches to drug discovery for hepatic fibrosis, and identify C1QTNF

197 we review the application of fragment-based drug discovery for the successful identification of nove

198 isomerases are still interesting targets for drug discovery for the treatment of several human diseas

199 utational platform to exploit fragment-based drug discovery for this important gene superfamily.

200 rein, we review the major advances in BACE-1 drug discovery, from single-target small molecule inhibi

201 With the advent of the Internet, drug discovery has become more decentralised, bottom-up,

202 Over the past decade, peptide drug discovery has experienced a revival of interest and

203 Transcriptome-based drug discovery has identified new treatments for some co

204 phosphorylation networks and in target-based drug discovery has long been recognized, the significanc

205 At the same time fragment-based drug discovery has matured into a powerful and widely ap

206 The use of privileged structures in drug discovery has proven to be an effective strategy, a

207 Drug discovery has undergone major transformations in th

208 Modern drug discovery highly depends on the identification and

209 xtends to three other cell lines relevant to drug discovery: human embryonic kidney (HEK293), cervica

210 D may represent a novel antiviral target for drug discovery.IMPORTANCE Picornaviruses remain an impor

211 escription of the recent progress in peptide drug discovery in a holistic manner, highlighting enabli

212 promising potential of STEP as a target for drug discovery in Alzheimer's treatment.

213 s a promising new direction for module-based drug discovery in human diseases such as PD.

214 ur study provides a framework for target and drug discovery in other cancers that lack known genetic

215 s and analgesics, has been a major focus for drug discovery in the recent past.

216 ignaling axis arouses a high interest in the drug discovery industry as it has been implicated in sev

217 grated our methodology with state of the art drug discovery instrumentation (FLIPR Tetra) and used se

218 Fragment-based drug discovery is an increasingly popular method to iden

219 The history of ALS drug discovery is fraught with many stops and starts.

220 se of this directing group in pharmaceutical drug discovery is illustrated by diversification of Telm

221 necessary to prevent ADR, the rapid pace of drug discovery makes it challenging to maintain a strong

222 ion sequencing (NGS) analysis, computational drug discovery, medical informatics, cancer genomics, an

223 and to benchmark a variety of computer-aided drug discovery methods under identical experimental cond

224 this work, a departure from the traditional drug discovery mindset was pursued, in which the enzyme'

225 heaper and faster alternative to traditional drug discovery offering a promising venue for orphan dru

226 d systems provide exciting new prospects for drug discovery, offering the possibility to perform comp

227 recently emerged as a systematic approach to drug discovery on a genome-wide scale.

228 In the context of drug discovery or drug repositioning, the methods presen

229 However, ongoing changes to pharmaceutical drug discovery organizations and practices threaten to u

230 e an integral part of the current industrial drug discovery paradigm.

231 nvenient tool to guide organic synthesis and drug discovery, particularly applicable to catalytic sys

232 es in optogenetics have opened new routes to drug discovery, particularly in neuroscience.

233 rief history of the field is surveyed from a drug discovery perspective with a focus on the key advan

234 e stage for the development of LMIPs a novel drug-discovery platform and class of materials to target

235 Here we use the "Inverse Drug Discovery" platform to identify and validate covale

236 al practice in obstructive lung disease, and drug discovery platforms was invited to participate in o

237 approaches used in high-throughput screening drug discovery platforms, for example, bright-field, pha

238 enhance the sensitivity of C. elegans based drug discovery platforms.

239 Here we establish a drug discovery process built on scalable phenotypic assa

240 partnerships were usually bilateral, and the drug discovery process was shrouded in secrecy.

241 nt but overlapping levels of openness in the drug discovery process.

242 core and the experimental data to impact the drug discovery process.

243 roaches can greatly speed up the traditional drug discovery process.

244 Herein, we describe a drug discovery program aiming at the identification of n

245 1) antagonists were the starting point for a drug discovery program that culminated in the discovery

246 que ADME assays of our irreversible covalent drug discovery program which culminated in the discovery

247 ibitor of Mps1 that was identified through a drug-discovery program.

248 Here we describe a multinational drug discovery programme that has delivered a synthetic

249 r research and the revitalisation of dormant drug-discovery programmes.

250 to be important pharmacophores in one of our drug discovery programs and endeavored to devise an asym

251 The chemical space explored in drug discovery programs is restricted by a narrow reacti

252 observation in high-throughput screening and drug discovery programs is the inhibition of protein fun

253 Significant investments in therapeutic drug discovery programs over the past two decades have y

254 proaches to label radioligands necessary for drug discovery programs remains a significant task.

255 tool-box to identify lead compounds for mIDH drug discovery programs, as well as what we believe is t

256 d HX, GSN and AAT as potential leads for new drug discovery programs.

257 o-arrhythmia and cardiotoxicity screening in drug discovery programs.

258 models is a decisive step of all preclinical drug discovery programs.

259 frequency makes it a key area of research in drug discovery programs.

260 pressure and suggest novel routes for future drug discovery programs.

261 ations of this animal model in protein-based drug discovery programs.

262 Underpinning all drug discovery projects is the interaction between a dru

263 ave emerged as attractive targets for cancer drug discovery, prompting immense interest in epigenetic

264 for applications in disease investigations, drug discovery, prosthetic design and neuropathic pain i

265 n order to demonstrate their suitability for drug discovery purposes.

266 The low success rate and high cost of drug discovery requires the development of new paradigms

267 e generated further interest in the field of drug discovery research, although the exact mechanisms o

268 al compounds are pivotal diagnostic tools in drug discovery research, providing vital information abo

269 variable to obtain reliable measurements for drug discovery research.

270 acterization of other therapeutic targets in drug discovery research.

271 -operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal re

272 So far, drug discovery strategies have been unsuccessful, becaus

273 exploit this approach to develop a rational drug discovery strategy against Abeta42 aggregation that

274 Here, we present a novel drug discovery strategy that combines a computational dr

275 ns from within cells, has emerged as a novel drug discovery strategy with the potential to offer ther

276 edict represents an innovative computational drug- discovery strategy to uncover drugs that are routi

277 Herein, we exemplify an "Inverse Drug Discovery" strategy in which organic compounds of i

278 The "Inverse Drug Discovery" strategy should be particularly attracti

279 will be readily applicable to protein-based drug discovery studies that utilize C. elegans as a mode

280 thus have contributed to valuable assays in drug discovery studies.

281 identified via solvent mapping to aid future drug discovery studies.

282 Applications in, e.g., drug discovery, synthesis, and toxicology studies are en

283 1 in pathogenic mycobacteria, as a candidate drug discovery target for tuberculosis and leprosy.

284 ew class of PDE-based complexes for specific drug discovery targeting the cAMP signaling pathway.

285 In conclusion, drug discovery targeting the gut microbiota as well as t

286 ch makes these pumps important antibacterial drug discovery targets.

287 hlight multiple cheminformatic approaches in drug discovery that can influence and triage design and

288 P) are exciting and novel targets for cancer drug discovery that work in concert with protein tyrosin

289 phase measurements in structural biology and drug discovery, the factors that govern protein stabilit

290 tant source for chemical entities supporting drug discovery, the rich traditions of herbal medicine d

291 the potential to bring disruptive change to drug discovery; the many potential advantages and outsta

292 le-cell imaging has been proven effective in drug discovery to evaluate drug-induced phenotypic varia

293 sion of tau pathology as well as tau-focused drug discovery to identify disease-modifying therapies f

294 g the first evidence for transcriptome-based drug discovery to target an addiction trait.

295 attractive for a wide range of assays, from drug discovery to toxicology, stem cell research and the

296 in(s), which may lead to chemical biology or drug discovery tools.

297 cells can be further applied in UPR-targeted drug discovery towards the development of disease-modify

298 omplex substrates that should be relevant to drug discovery, where fluorine plays a prominent role.

299 structure-guided design with fragment-based drug discovery, which reduces the size of screening libr

300 unities that silicon incorporation offers in drug discovery, with an emphasis on case studies where i